Modern Fertility Presented Clinical Study on Minimally Invasive Testing for Fertility and Nominated for Prize Paper at ASRM Annual Meeting

The study titled, “The Evaluation of a Novel, Minimally Invasive Test
for Fertility Hormones,” supports the notion that minimally invasive
testing methods and traditional blood draw can be used interchangeably

SAN FRANCISCO–(BUSINESS WIRE)–Modern
Fertility
, the women’s health company that makes fertility
information more accessible, presented its study on minimally invasive
testing for reproductive hormones at the 74th Scientific Congress & Expo
of the American Society for Reproductive Medicine (ASRM). Dr. Erin
Burke, PhD, presented the results of a clinical study entitled, “The
Evaluation of a Novel, Minimally Invasive Test for Fertility Hormones.”
The study supports that venipuncture and fingerstick samples can be used
interchangeably to measure eight reproductive health hormones in women.

Furthermore, the clinical study was nominated by ASRM for the Scientific
Congress’s Prize Paper in this year’s Annual Meeting.

The scientific abstract, which will be published in Fertility and
Sterility
, revealed for the first time that minimally invasive
testing methods and traditional blood draw can be used interchangeably
to measure eight reproductive hormones in women, with a correlation of
1.0 to .99 between the two methods, depending on the hormone tested.
Fingerstick sampling allows for women to test reproductive hormone
levels at home––giving both women trying to conceive and women planning
for future fertility the ability to take ownership over their
reproductive options.

“We see this collection method applied widely throughout other health
industries, from nutrition monitoring to screening of diseases like HIV.
This is a huge step forward, as the women’s health industry deserves the
latest advancements,” says Dr. Erin Burke, Head of Research for Modern
Fertility. “Validating the effectiveness of the minimally invasive test
offers a more accessible option to gain this information earlier in
life.”

The study compared venipuncture and fingerstick samples from women ages
18 to 40 on menstrual cycle day three.

Samples were measured for anti-Müllerian hormone (AMH), estradiol, (E2),
follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin
(PRL), testosterone (T), thyroid stimulating hormone (TSH), and free
thyroxine (fT4), and were tested using FDA-cleared immunoassays, with a
modified reconstitution step for fingerstick samples. Calculations were
compared with the optimal clinically significant limits established by
the European Federation of Clinical Chemistry and Laboratory Medicine
(EFLM).

“Being a company that provides women with critical information about
their reproductive health, it is paramount that we deliver
medically-sound results,” says co-founder and CEO of Modern Fertility,
Afton Vechery. “We view ourselves as an education provider first and
foremost, and the development of our testing is deeply rooted in the
most up to date scientific research. Confidently bringing that research
into the homes of women is now made possible, and through a much more
accessible process.”

The Modern Fertility test is currently the most comprehensive tool
available to measure reproductive hormones using minimally invasive
fingerstick testing, with every test run in a CLIA and CAP accredited
lab. It enables women to gain easier access to information on their
hormone levels, which can also help educate women on conditions such as
polycystic ovarian syndrome or primary ovarian insufficiency. This
clinical study supports Modern Fertility’s notion to not only make
fertility information more affordable, but to put the power of fertility
knowledge in the hands of women whenever they want it.

ABOUT MODERN FERTILITY

Modern Fertility is a women’s health company that empowers all women to
make informed decisions about their health, starting with fertility.
Modern Fertility takes the same lab tests previously confined to
fertility clinics and makes them more accessible by allowing women to
take the tests at home or in a nearby lab for a fraction of the cost. By
educating women and arming them with powerful information about their
reproductive health, the company is closing the fertility information
gap and enabling women to have more data for decision-making. Co-founded
by Afton Vechery and Carly Leahy, Modern Fertility has raised a total of
$7 million to advance fertility science so women can learn more about
their bodies on their own terms.

The Modern Fertility test is $199 and includes free shipping. Tests are
available online at www.modernfertility.com.

ABOUT THE AMERICAN SOCIETY OF REPRODUCTIVE MEDICINE:

ASRM is a multidisciplinary organization dedicated to the advancement of
the science and practice of reproductive medicine. For more information,
visit www.asrm.org.

Contacts

Melanie Galang for Modern Fertility
modernfertility@moxiegrouppr.com

leverton

I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.coom for scheduling information.